NCT05723289

Brief Summary

The implementation of an mechanical in-exsufflator device (MI-E) requires specific expertise because it is a complex device that requires fine-tuning of the settings according to different clinical situations to optimize its effectiveness. Generally, it is performed by experienced physiotherapists in neuromuscular disease reference centers or directly at home via medical-technical home care providers. Treatment data is recorded by the machine at each MI-E session, which may be daily or less frequent, depending on the patient's dependency. All of this information can be accessed by manually downloading the data from the SD card that comes with each MI-E machine. Therefore, the retrieval of this information systematically requires the visit of staff to the patient's home. To date, compliance with these devices is not regularly measured since there is no means of telecommunication allowing remote monitoring of these therapies, whereas technological development in the field of remote monitoring has allowed remote monitoring of patients with sleep apnea syndrome treated with continuous positive airway pressure (CPAP) and, more recently, of some patients with chronic respiratory insufficiency treated with invasive ventilation (NIV). These developments are transforming on the one hand the follow-up of patients under NIV at home by the medical and paramedical teams and on the other hand the financial coverage by the health insurance organizations (ETAPES programs). Within the framework of NIV therapy, we think that remote monitoring of the quality of the sessions, i.e. measurement of peak expiratory flow, insufflated volumes, frequency and duration of the sessions, could facilitate and improve the follow-up of these patients for the medical-technical providers, the expert physiotherapists and the doctors of the reference centers. It is still too early to assume the extent to which data from remote monitoring of MI-E devices would improve patient follow-up. Nevertheless, given the increasing number of devices installed over the past several years, it is likely that the issue of telemonitoring will become a central issue. Thus, in this observational trial, we propose to evaluate the feasibility of a simple system of remote monitoring of MI-E devices in non-therapy-naive patients, with the objective of assessing the barriers and limitations of remote monitoring in this population. Primary aim is to evaluate the feasibility of remote monitoring of data from the MI-E device used in the patient's home in neuromuscular diseases. Patients will be identified by the investigators using the AGIR à dom software package (medical-technical follow-up file). If the patient accepts, the information and no-objection form will be sent to them electronically or by mail following this call, and at least 3 days before their scheduled appointment. During the patient's usual follow-up visit, if the patient does not object to participating in the study, AGIR staff in dom will install the device. This visit will take place in the patient's home. During this visit, a SanDisk (SD) Eye-Fi SDHC 4GB + WiFi Class4 memory card will be inserted into the port provided, in place of the memory card already present in the MI-E device. Then a Raspberry Pi 4 Model B will be placed in the room where the MI-E device is normally used by the patient, and connected to a power source (accessible electrical outlet in the room). The wifi SD card, which uses the device's power supply, will communicate with the Raspberry Pi via the wifi network and upload the recorded data each time the MI-E device is used. After 90 days, a routine recovery visit will be scheduled. AGIR à dom staff will replace the wifi SD card installed during the D0 visit with the standard SD card originally provided with the MI-E device. The data locally on the SD Wifi card will then be downloaded for analysis and comparison with the data being uploaded

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 3, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 10, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

June 1, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

June 23, 2023

Status Verified

June 1, 2023

Enrollment Period

6 months

First QC Date

February 3, 2023

Last Update Submit

June 22, 2023

Conditions

Keywords

Neuromuscularscoliosis

Outcome Measures

Primary Outcomes (1)

  • Feasibility of remote monitoring of data from the MI-E device used in the patient's home.

    The difference between the number of sessions of device use uploaded and the actual number of sessions performed, collected from the internal memory of the device.

    90 days

Secondary Outcomes (3)

  • Compare cost of telemonitoring versus cost of monitoring by a technician in the patient's home

    90 days

  • Describe the type of data collected through remote monitoring of MI-E devices

    90 days

  • Identify the factors limiting the implementation of telemonitoring

    90 days

Interventions

Daily telemonitoring using a ad-hoc communicating device

Eligibility Criteria

Age18 Years - 115 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Neuromuscular disease or paralytic

You may qualify if:

  • Male or female patient over 18 years of age
  • Patients with neuromuscular or paralytic disease
  • Patient previously treated with an E70 in-exsufflation device (Philips Respironics)
  • Patient with known use of the E70 in-exsufflation device at least once a week, excluding episodes of infection.
  • Patient followed by AGIR at home
  • Patient willing to participate in the research after adequate information and delivery of the information note.
  • Patient affiliated to the social security system or beneficiary of such a system.

You may not qualify if:

  • No internet solution at home (adsl/fibre box)
  • Technical inability to connect the computer to the Internet by Ethernet cable
  • Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure (patient under guardianship or curatorship) Article L1121-8.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Borel Jean-Christian

Meylan, France

RECRUITING

MeSH Terms

Conditions

Neuromuscular DiseasesScoliosis

Condition Hierarchy (Ancestors)

Nervous System DiseasesSpinal CurvaturesSpinal DiseasesBone DiseasesMusculoskeletal Diseases

Central Study Contacts

Marius G Lebret, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 3, 2023

First Posted

February 10, 2023

Study Start

June 1, 2023

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

June 23, 2023

Record last verified: 2023-06

Locations